共 50 条
Novel treatment for immune neuropathies on the horizon
被引:9
|作者:
Hartung, Hans-Peter
[1
]
Lehmann, Helmar C.
[1
]
Kieseier, Bernd C.
[1
]
Hughes, Richard A. C.
[2
]
机构:
[1] Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany
[2] UCL, MRC Neuromuscular Dis Ctr, Inst Neurol, London, England
关键词:
autoimmunity;
inflammation;
monoclonal antibodies;
neuromuscular diseases;
neuropathy;
INFLAMMATORY-DEMYELINATING POLYNEUROPATHY;
GUILLAIN-BARRE-SYNDROME;
MULTIFOCAL MOTOR NEUROPATHY;
EXPERIMENTAL AUTOIMMUNE NEURITIS;
RELAPSING MULTIPLE-SCLEROSIS;
PLACEBO-CONTROLLED TRIAL;
PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA;
COMPLEMENT INHIBITOR ECULIZUMAB;
RANDOMIZED CONTROLLED-TRIAL;
B-CELL DEPLETION;
D O I:
10.1111/j.1529-8027.2011.00334.x
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Immune neuropathies represent a heterogeneous spectrum of acute and chronic peripheral nerve disorders of autoimmune origin. Despite the current available treatment options, immune neuropathies are still associated with severe neurological deficits and poor clinical prognosis. However, during the last years, significant advances have been made in unraveling some of the underlying pathomechanisms. The exploration of novel therapeutic approaches including monoclonal antibodies and oral immunosuppressants, known from other autoimmune disorders such as multiple sclerosis, suggests new approaches to treatment. Here, we review the available clinical data as well as the scientific rationale and expected benefits and risks for these strategies.
引用
收藏
页码:75 / 83
页数:9
相关论文